By Frederick W. Alt

Advances in Immunology offers present advancements in addition to accomplished stories in immunology. Articles deal with the big variety of subject matters that include immunology, together with molecular and mobile activation mechanisms, phylogeny and molecular evolution, and scientific modalities. Edited and authored by means of the most important scientists within the box, every one quantity presents up to date info and instructions for destiny research.

  • Contents of volumes 66-82
  • Cumulative topic Index
  • List of Contributors
  • Highly revered evaluate sequence with an impression think about 2003 of 10.49 and ranked quantity nine /119

Show description

Read Online or Download Advances in Immunology, Volume 85: Cumulative Subject Index, Volumes 66-82 PDF

Best science (general) books

Advances in Child Development and Behavior (Volume 33)

The Advances in baby habit and improvement sequence has a well-merited attractiveness for publishing seminal articles that stream proven courses of developmental scholarship ahead in artistic new instructions. in keeping with this acceptance, the articles in quantity 33 of the sequence provide ground-breaking paintings on issues as varied as kid's problem-solving options, intentionality, mathematical reasoning, and socialization inside and past university settings.

Advances in Mergers and Acquisitions, Volume 3 (Advances in Mergers and Acquisitions)

This is often the 3rd publication within the sequence "Advances in Mergers and Acquisitions", produced from best foreign students from a number of disciplines, who discover the commercial, monetary, strategic or organizational behaviour elements of M & A's. Marie Kavanagh and Neal Ashkanasy discover how administration methods to mergers and acquisitions give a contribution to cultural swap and acculturation results.

Extra info for Advances in Immunology, Volume 85: Cumulative Subject Index, Volumes 66-82

Sample text

82:7–9 Arterial thrombosis, 70:513 Arthritis, see also Rheumatoid arthritis adjuvant, 82:228 antigen-induced (AIA), 82:224–225, 234–235 collagen-induced, 68:369–371, 375–377, 393–394; 73:272 collagen-induced (CIA), 82:223–224, 234–235 in HTLV mouse, 82:230–231 in IL-lra mouse, 82:232 immunizations and, 82:232–233, 234–235 in Ipr mouse, 82:230 K/BxN, 82:228–230, 235 mutant IL-6 mouse, 82:232 non-rheumatoid juvenile, 68:352 other models for, 82:232–233 pristane-induced, 82:226–227 proteoglycan-induced (PGIA), 82:226, 234–235 psoriatic, 82:233 rheumatoid, see Rheumatoid arthritis septic, 73:460–461 streptococcal cell wall (SCW), 82:226–227 zymosan-induced, 82:227–228 17 Arthritis, collagen-induced, 70:162–164 Arthritis, rheumatoid (RA), 82:235–238, see also Rheumatoid factors adjuvant arthritis and, 82:228 AIA and, 82:224–225 animal models of, 82:222 CIA and, 82:223–224 cytokines/macrophages and, 82:219 effector mechanisms and, 82:220–222 features of, 82:217 fibroblasts and, 82:219, 308 K/BxN arthritis and, 82:228–230 MHC and, 82:217–218 mouse models of, 82:217–237 PGIA and, 82:226 pristane-induced arthritis and, 82:227 SCW and, 82:226 T cells and, 82:217–218 theories of, 82:217–219 zymosan-induced arthritis and, 82:227–228 Arthritis, rheumatoid, 69:364 ASC-MUC1, see MUC1purified from ascites fluid of cancer patients Asparaginyl endopeptidase antigen degradation by, 80:100 present in APCs, 80:76 Assays, early thymocyte development in vitro, 69:3–4 in vivo, 69:5–6 18 SUBJECT INDEX Asthma, 72:293–294; 82:21–22, 113–114 ABCD chemokine role, 78:148–149 CpG DNA role, 73:350–351 gastrointestinal eosinophils, 78:319–320 IL-8 production, 73:427 industrial model of, chemical compounds in, 77:267 RSV association with, 77:285–286 Ataxia telangiectasia (AT), 82:315–316 Ataxia telangiectasia, 69:311 Ataxia-telangiectasia gene, 72:180–181 lymphoid defects characterization, 72:179 dissecting, 72:181–185 tumorigenesis characterization, 72:179 dissecting, 72:181–185 ATF-2, transforming growth factor-b signaling, 75:131 Atherosclerosis, 69:367 autoimmune hypothesis, 80:263–265 HSP 60 and, 80:273 Atherosclerosis, sPLA2-IIA role, 77:177 ATM, 72:180–181 Atopic dermatitis, ABCD chemokine role, 78:149–150 Atopic disorders, 68:115–116 Atopy, 82:114 ATP, see Adenosine triphosphate ATP, protein degradation dependent on, 80:3 ATPase, in 26S proteasome base, 80:10–11 ATPases, in xenotransplantation, 79:170–171 Atrophy organ, 80:246–247 thymus, cytokines and, 80:269–270 Auto-Abs, 82:236 Auto-antibody responses, B cell induction, 79:19–21 Autoimmune disease, 69:363–364, 367–368; 81:331 abnormality in Treg cells, 81:335–336 HLA and, 66:67, 76, 84–85, 93 insulin-dependent diabetes mellitus, 66:91 methimazole-induced insulin autoimmune syndrome, 66:87–88 multiple sclerosis, 66:88–91 pemphigus vulgaris, 66:87 rheumatoid arthritis, 66:85, 87 immunointervention, 66:91–93 organ-specific, 70:157–158 pregnancy effects, 70:519 spontaneous, 70:165–166 Autoimmune disease, T-cell receptor crossreactivity role, 75:209–226 cytokine checkpoints, 75:223–226 low affinity ligands, 75:211–214 overview, 75:209 peripheral purging of useless T cells, 75:218–220 peripheral T-cell tolerance, 75:214–217 19 SUBJECT INDEX T-cell antagonism, 75:211–217 viral-derived peptide agonists, 75:220–223 Autoimmune diseases, see also specific diseases animal model studies, 68:365–397 anti-CD7 monoclonal antibodies and, 68:358–359 apoptosis and, 68:51, 100 CD30 and, 68:115–116 cytokine treatment, 68:337–347 DR3 production, 73:286–287 interleukin-2 targeted approach to, 68:359–361 major histocompatibility complex and, 68:385–386 monoclonal antibodies and anti-CD4, 68:347–353 anti-CD5, 68:353–358 anti-CD7, 68:358–359 oral tolerance animal models, 73:218–223 humans, 73:227–228 worsening, 73:223–224 peptide transporters and, 68:226–228, 238–239 preventive therapy, 68:395 T cell receptor costimulation and, 68:381–385 TNF-a implications, 73:275–277 TRAIL production, 73:286–287 Autoimmune lymphoproliferative syndrome, 71:167 Autoimmune response, 69:363, 383, 387 Autoimmune vascular disease, 70:531–532 Autoimmunity control by naturally arising regulatory CD4þ T cells, 81:329–369 Treg cells in spontaneous models of, 81:335 Autoimmunity, B cell induction, 79:19–21 Autonomic nervous system, 81:143 Autoreactivity, 69:150–152, 155–156 AUUUA motifs AU-B and AU-C binding requirement, 68:34 in AU-binding factor, 68:30–31 in c-fos and c-myc mRNAs, 68:27–28 in ICAM-1, 68:27 long term repeats and, 68:22 in mRNA regulation, 68:5–8, 11–15, 19 Auxiliary factor (ACF), 82:306 Avascular necrosis of bone, 70:518–519 Avery, O.

82:7–9 Arterial thrombosis, 70:513 Arthritis, see also Rheumatoid arthritis adjuvant, 82:228 antigen-induced (AIA), 82:224–225, 234–235 collagen-induced, 68:369–371, 375–377, 393–394; 73:272 collagen-induced (CIA), 82:223–224, 234–235 in HTLV mouse, 82:230–231 in IL-lra mouse, 82:232 immunizations and, 82:232–233, 234–235 in Ipr mouse, 82:230 K/BxN, 82:228–230, 235 mutant IL-6 mouse, 82:232 non-rheumatoid juvenile, 68:352 other models for, 82:232–233 pristane-induced, 82:226–227 proteoglycan-induced (PGIA), 82:226, 234–235 psoriatic, 82:233 rheumatoid, see Rheumatoid arthritis septic, 73:460–461 streptococcal cell wall (SCW), 82:226–227 zymosan-induced, 82:227–228 17 Arthritis, collagen-induced, 70:162–164 Arthritis, rheumatoid (RA), 82:235–238, see also Rheumatoid factors adjuvant arthritis and, 82:228 AIA and, 82:224–225 animal models of, 82:222 CIA and, 82:223–224 cytokines/macrophages and, 82:219 effector mechanisms and, 82:220–222 features of, 82:217 fibroblasts and, 82:219, 308 K/BxN arthritis and, 82:228–230 MHC and, 82:217–218 mouse models of, 82:217–237 PGIA and, 82:226 pristane-induced arthritis and, 82:227 SCW and, 82:226 T cells and, 82:217–218 theories of, 82:217–219 zymosan-induced arthritis and, 82:227–228 Arthritis, rheumatoid, 69:364 ASC-MUC1, see MUC1purified from ascites fluid of cancer patients Asparaginyl endopeptidase antigen degradation by, 80:100 present in APCs, 80:76 Assays, early thymocyte development in vitro, 69:3–4 in vivo, 69:5–6 18 SUBJECT INDEX Asthma, 72:293–294; 82:21–22, 113–114 ABCD chemokine role, 78:148–149 CpG DNA role, 73:350–351 gastrointestinal eosinophils, 78:319–320 IL-8 production, 73:427 industrial model of, chemical compounds in, 77:267 RSV association with, 77:285–286 Ataxia telangiectasia (AT), 82:315–316 Ataxia telangiectasia, 69:311 Ataxia-telangiectasia gene, 72:180–181 lymphoid defects characterization, 72:179 dissecting, 72:181–185 tumorigenesis characterization, 72:179 dissecting, 72:181–185 ATF-2, transforming growth factor-b signaling, 75:131 Atherosclerosis, 69:367 autoimmune hypothesis, 80:263–265 HSP 60 and, 80:273 Atherosclerosis, sPLA2-IIA role, 77:177 ATM, 72:180–181 Atopic dermatitis, ABCD chemokine role, 78:149–150 Atopic disorders, 68:115–116 Atopy, 82:114 ATP, see Adenosine triphosphate ATP, protein degradation dependent on, 80:3 ATPase, in 26S proteasome base, 80:10–11 ATPases, in xenotransplantation, 79:170–171 Atrophy organ, 80:246–247 thymus, cytokines and, 80:269–270 Auto-Abs, 82:236 Auto-antibody responses, B cell induction, 79:19–21 Autoimmune disease, 69:363–364, 367–368; 81:331 abnormality in Treg cells, 81:335–336 HLA and, 66:67, 76, 84–85, 93 insulin-dependent diabetes mellitus, 66:91 methimazole-induced insulin autoimmune syndrome, 66:87–88 multiple sclerosis, 66:88–91 pemphigus vulgaris, 66:87 rheumatoid arthritis, 66:85, 87 immunointervention, 66:91–93 organ-specific, 70:157–158 pregnancy effects, 70:519 spontaneous, 70:165–166 Autoimmune disease, T-cell receptor crossreactivity role, 75:209–226 cytokine checkpoints, 75:223–226 low affinity ligands, 75:211–214 overview, 75:209 peripheral purging of useless T cells, 75:218–220 peripheral T-cell tolerance, 75:214–217 19 SUBJECT INDEX T-cell antagonism, 75:211–217 viral-derived peptide agonists, 75:220–223 Autoimmune diseases, see also specific diseases animal model studies, 68:365–397 anti-CD7 monoclonal antibodies and, 68:358–359 apoptosis and, 68:51, 100 CD30 and, 68:115–116 cytokine treatment, 68:337–347 DR3 production, 73:286–287 interleukin-2 targeted approach to, 68:359–361 major histocompatibility complex and, 68:385–386 monoclonal antibodies and anti-CD4, 68:347–353 anti-CD5, 68:353–358 anti-CD7, 68:358–359 oral tolerance animal models, 73:218–223 humans, 73:227–228 worsening, 73:223–224 peptide transporters and, 68:226–228, 238–239 preventive therapy, 68:395 T cell receptor costimulation and, 68:381–385 TNF-a implications, 73:275–277 TRAIL production, 73:286–287 Autoimmune lymphoproliferative syndrome, 71:167 Autoimmune response, 69:363, 383, 387 Autoimmune vascular disease, 70:531–532 Autoimmunity control by naturally arising regulatory CD4þ T cells, 81:329–369 Treg cells in spontaneous models of, 81:335 Autoimmunity, B cell induction, 79:19–21 Autonomic nervous system, 81:143 Autoreactivity, 69:150–152, 155–156 AUUUA motifs AU-B and AU-C binding requirement, 68:34 in AU-binding factor, 68:30–31 in c-fos and c-myc mRNAs, 68:27–28 in ICAM-1, 68:27 long term repeats and, 68:22 in mRNA regulation, 68:5–8, 11–15, 19 Auxiliary factor (ACF), 82:306 Avascular necrosis of bone, 70:518–519 Avery, O.

82:50 AVN, see Avascular necrosis of bone AXB cells, 73:59 Axons, guidance to appropriate targets, 81:173 Azathioprin, 68:356 B B-cell attracting chemokine-1 (BCA-1), 81:6 B-cell development CD100 in, 81:183–184 in teleosts, 81:282–285 in zebrafish pancreas, 81:284–285 20 SUBJECT INDEX B-cell differentiation, 81:103 B-cell lineage lymphomas, 81:99, 103 B-cell lineage lymphomas/ leukemias, human and mouse, 81:105 B-cell lineage neoplasms, 81:100, 113–115 B-cell lymphomas, 81:238–239 B-cell receptor (BCR), 81:286 B-cell receptors and ITAMs, 69:186, 205–206, 208, 211–212 and SHP-1, 69:222–223 structure of, 69:186–189 B-cells, 81:5, 47, 130, 134–136 self-reactive, 81:329 zebrafish, 81:255 b-globin, 68:19, 20, 25, 26 B-lineage cells, transformation, 81:111 B-lymphocytes, 81:47, 130 B-natural killer cell lymphoma, 81:105 B7 molecules, 68:280, 382–385 B1 receptors, 66:239, 240 B2 receptors, 66:240 Bacille Calmette Gue´ rin antigen carrier role, 75:49–53 tuberculosis vaccination, 75:29, 46–47 Bacillus Calmettte-Gue´ rin (BCG), 82:270 Bacteria, 69:295; 72:294 major histocompatibility complex class II antigen presentation subversion, 75:189–191 vaccinology, see Vaccines Bacteria, see also specific bacterium artificial particles, 73:32–34 DNA, CpG motifs as antitumor adjuvant, 73:349–350 cellular uptake, 73:333 CTL response, 73:353–354 evolution, 73:346–348 extramedullary hematopoiesis-induced, 73:351 immune cell activation, 73:352 immune response, 73:331–332 mediative effects in vivo, 73:349 as mucosal adjuvant, 73:351 sequence effects APCs, 73:336–338 B cells, 73:334–335 immunosuppressive, 73:342 independent, 73:333–334 macrophage receptors, 73:341 NK cells, 73:339 T cells, 73:338–339 TNF-a production, 73:342 signal mediation cell response, 73:352–353 cellular uptake, 73:343–344 chloroquine effects, 73:346 lysosomotropic compounds, 73:344–345 stress kinase pathway, 73:345–346 T cell effects as Th1 adjuvant, 73:348–349 Th2 pathology, 73:350–351 infections in vivo, 73:467–468 protein presentation, 73:26–32 Bacteria, see also specific species Bcl-2 homology, 70:263–264 IL-12 inhibition, 70:177–181 SUBJECT INDEX Bacteria, interleukin-12 induction, 79:62–63 Bacterial DNA, 69:372–373 Bacterial pathogens, intracellular survival of, 81:65–70 Bacteriophage, DNA delivery, 75:58–59 Baculovirus, 68:60, 120, 216–217 BAF chromatin-remodeling complex, lymphocyte signaling role, 75:109–110 Bafilomycin A, 73:346 Bagnara, G.

Download PDF sample

Rated 4.37 of 5 – based on 28 votes